More Arovella Therapeutics Limited news
Arovella Therapeutics LimitedASX: ALA

Response to ASX Query

Apr 26, 2023 at 7:20 AM EDT · Issued by Arovella Therapeutics Limited

Filed with ASX · Apr 26, 2023 at 7:20 AM EDT

On 6ix: 6ix.com/news/response-to-asx-query-50

Arovella Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Arovella Therapeutics Limited on 6ix

Earlier from Arovella Therapeutics

  • Response to ASX Aware QueryApr 20, 2023
  • ALA-101 confers survival benefit in leukemia modelApr 16, 2023
  • Arovella completes $1.65M placementJan 18, 2023
  • R&D Tax Incentive refund receivedNov 29, 2022
  • Europe Patent granted for iNKT Cell Therapy PlatformNov 6, 2022

Later from Arovella Therapeutics

  • Arovellas OroMist R&D facility closure completedMay 1, 2023
  • Arovella completes $4M placement & launches $1M sppJun 7, 2023
  • Share Purchase Plan (SPP) Offer BookletJun 14, 2023
  • Share Purchase Plan (SPP) Closing Date ExtendedJun 28, 2023
  • Completion of oversubscribed Share Purchase Plan (SPP)Jul 10, 2023
All Arovella Therapeutics news releases↗

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer